797. Tuberculosis Treatment: Combined Forms vs Dissociated Forms
Session: Poster Abstract Session: Tuberculosis and Other Mycobacterial Infections
Thursday, October 4, 2018
Room: S Poster Hall
Background:

Tuberculosis treatment is based on the regular and concomitant intake of several antibiotics. The goal of this multidrug therapy is to prevent the selection of mutants resistant. This combination drug comes in two regimens with dissociated forms (DF) and combined forms (CF). Our study aimed to compare both forms of anti-tubercular treatment.

Methods:

We retrospectively collected data from the regional registry of tuberculosis in the government of Sfax as a part of the National Tuberculosis Program. We included all new cases of tuberculosis from January 1995 to December 2016.

Results:

We counted 2771 cases of tuberculosis. There were 59.5% cases with extra-pulmonary (n=1650) forms and 40.5% with pulmonary forms (n=1121). The median age was 38 years (IQR= [25-55 years]) with a male predominance (n=1508; 54.4%). We noted that 72.9% of patients (n=1985) received the DF, 26.2% (n=714) received the CF and 0.8% (n=23) received both forms of treatment. DF was significantly more prescribed in patients with extra-pulmonary tuberculosis (75.4% vs. 72%; OR=0.837; p=0.043) whereas CF was significantly prescribed in patients with pulmonary tuberculosis (28% vs. 24.6%; OR=0.837; p=0.043). DF was more used in patients with primary tuberculosis infection (30.3% vs. 21.6%; OR=0.632; p<0.001). The duration of treatment was significantly higher in patients who received DF (9 months vs. 8 months; p<0.001). We did not find a difference in the evolution between patients treated with DF and those treated with CF.

Conclusion:

CF are of a great importance to ensure better compliance and synergistic effects of different antibiotics with a reduced duration.

Maroua Trigui, MD1, Makram Koubaa, MD2,3, Houda Ben Ayed, MD1,3, Chakib Marrakchi, MD2,3, Fatma Hammami, MD2,3, Tarak Ben Jemaa, MD2,3, Jamel Dammak, MD1 and Mounir Ben Jemaa, MD2,3, (1)Department of Community Health and Epidemiology, Hedi Chaker University Hospital, Sfax, Tunisia, (2)Department of Infectious Diseases, Hedi Chaker University Hospital, Sfax, Tunisia, (3)Extrapulmonary Tuberculosis Research Unit, Hedi Chaker University Hospital, Sfax, Tunisia

Disclosures:

M. Trigui, None

M. Koubaa, None

H. Ben Ayed, None

C. Marrakchi, None

F. Hammami, None

T. Ben Jemaa, None

J. Dammak, None

M. Ben Jemaa, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.